AI-Powered News Analysis•Compare coverage across the political spectrum
GoodPointsNews
Admin
Back to Dashboard
Novo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com

Novo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com

Novo CEO says obesity market won't be winner-take-all battle with Lilly reuters.com

August 13, 2026 at 10:02 AM Original source
1 agencies covered this story

Coverage by Political Leaning

See how different sides of the spectrum reported this story

Left
0 articles
No coverage
Lean Left
0 articles
No coverage
Center
1 articles
Lean Right
0 articles
No coverage
Right
0 articles
No coverage

Notable Quotes

"The obesity market won't be a winner-take-all battle with Lilly."

— CEO of Novo , Executive

Key People

C
CEO of NovoExecutive

The executive leading Novo in the obesity medications market.

Locations

denmark

Tags

business lilly market novo obesity pharma

All Coverage

Novo CEO says obesity market won't be winner-take-all battle with Lilly - reuters.com
Reutersvia rss 1 quote 1 person

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOTlNoUmF5ZWkzUTJQb3BzWVBBMENKTnBhUzAwWXowZkhYN3FONGFQVGRVYXhlRFB0SjhkdWdfSmNuUDB6VVMtZ2xNdnBBLTlYXzJILUZuZDZPd1hQV3VzTjd6cmlkQUNwQTU5b1NvNm1ONS15WmtVc3ZTNDNjNEZJWG1EaWR5bTFPM0UyOW54cElXNnZ1azUtWVlmTFFBS1A5M3l4OWcyT0pmMU1pemxFTmdwdk1idEFTSE9LeTdLRkw?oc=5" target="_blank">Novo CEO says obesity market won't be winner-take-all battle with Lilly</a>&nbsp;&nbsp;<font color="#6f6f6f">reuters.com</font>

100%

Similar Stories

Related coverage based on topic and tags

Experimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters

Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters

September 30, 2026 at 05:34 PM

Lilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com

Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com

September 29, 2026 at 10:15 PM

Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com

Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro reuters.com

September 29, 2026 at 09:49 PM

Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com

Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial reuters.com

September 30, 2026 at 10:30 PM

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study - Reuters

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Reuters

September 30, 2026 at 09:57 AM

Amazon, GoodRx target US prescription subscribers as health insurance coverage slips - reuters.com

Amazon, GoodRx target US prescription subscribers as health insurance coverage slips reuters.com

September 29, 2026 at 10:54 AM